Oct 10 (Reuters) - Akebia Therapeutics Inc :
* AKEBIA THERAPEUTICS INC: CMS GRANTS TDAPA REIMBURSEMENT FOR VAFSEO (VADADUSTAT) BEGINNING JAN 1, 2025
* AKEBIA THERAPEUTICS INC: TDAPA PROGRAM PROVIDES TWO YEARS OF REIMBURSEMENT FOR VAFSEO IN ADDITION TO ESRD BUNDLED RATE TO DIALYSIS ORGANIZATIONS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.